Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AARDVARK THERAPEUTICS, INC.

Aardvark Therapeutics, Inc. (NASDAQ: AARD)
Listen to this Section


$3.77
-0.1750 ( -4.44% ) 60.2K

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Market Data


Open $3.77
Previous Close $3.94
Volume 60.2K
Market Cap $85.96M
Day Range $3.73 - $4.04
52 Week Range $3.35 - $17.94
Shares Outstanding 21.82M
Change % -4.44%
Net Change ▼ -0.1750
Insider Ownership N/A
Exchange NASDAQ
SectorBasic Materials
IndustryPHARMACEUTICAL PREPARATIONS
IPO Year2025
CountryUnited States
UnderwriterMorgan Stanley, BofA Securities, Cantor Fitzgerald, RBC Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: 21,500.00

Date Type Amount Purchased Purchaser
2025-09-16 Buy 6500.00 Lee Tien-Li
2025-09-12 Buy 9000.00 Lee Tien-Li
2025-09-10 Buy 6000.00 Sun Nelson

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 13, 2025
4 Insider transactions 1 Jun 13, 2025
4 Insider transactions 1 Jun 13, 2025

Latest News


× Before browsing our site, please accept our cookies policy